SJ733首次人体及诱导血阶段疟疾1a/b期试验
该1a/b期试验评估了新型口服PfATP4抑制剂SJ733的安全性、耐受性、药代动力学及抗疟活性。1a期23名健康参与者中SJ733安全耐受;
要点
- SJ733在75-1200 mg剂量范围内安全耐受,仅1例轻度双侧足部感觉异常可能与药物相关。
核心结论
- SJ733具有良好的药代动力学、耐受性和安全性特征,以及快速抗寄生虫效应,支持其作为联合抗疟疗法中快速起效成分的进一步开发。
研究设计与样本
- 1a期为单中心、剂量递增、首次人体研究,允许根据安全性和药代动力学结果调整剂量递增和队列大小,在St Jude儿童研究医院和田纳西大学临床研究中心进行。
- 1b期为单中心、开放标签、志愿者感染研究,采用诱导血阶段疟疾模型,在Q-Pharm进行,仅当1a期显示可安全达到超过阈值最低暴露后才启动。
- 1a期纳入23名健康参与者,接受1至3次非连续剂量;1b期纳入17名疟疾初治健康参与者。
主要发现
- 1a期记录119例不良事件,其中54例(45%)无关,63例(53%)不太可能相关,2例(2%)可能与SJ733相关。
关键数值与推荐
- 1a期单次递增剂量为75、150、300、600、900或1200 mg,7个空腹队列和1个600 mg进食队列。
- 1b期150 mg队列接种约2800个寄生虫,600 mg队列接种约2300个寄生虫;当寄生虫密度达到5000个/mL或临床评分高于6时,在24小时内给予SJ733。
临床怎么用
- SJ733在健康受试者中安全耐受,600 mg剂量可达到超过目标阈值的暴露水平并显示快速抗疟活性,支持其作为联合抗疟疗法中快速起效成分进一步开发。
局限性
- 1b期600 mg队列中8名参与者接种,但2名未能接受SJ733给药,另有2名后续接种并给药。
- 1b期所有接受SJ733的15名参与者均发生至少1例不良事件,但多数为轻度且与疟疾相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: (+)-SJ000557733 (SJ733) is a novel, orally bioavailable inhibitor of Plasmodium falciparum ATP4. In this first-in-human and induced blood-stage malaria phase 1a/b trial, we investigated the safety, tolerability, pharmacokinetics, and antimalarial activity of SJ733 in humans. METHODS: The phase 1a was a single-centre, dose-escalation, first-in-human study of SJ733 allowing modifications to dose increments and dose-cohort size on the basis of safety and pharmacokinetic results. The phase 1a took place at St Jude Children's Research Hospital and at the University of Tennessee Clinical Research Center (Memphis, TN, USA). Enrolment in more than one non-consecutive dose cohort was allowed with at least 14 days required between doses. Participants were fasted in seven dose cohorts and fed in one 600 mg dose cohort. Single ascending doses of SJ733 (75, 150, 300, 600, 900, or 1200 mg) were administered to participants, who were followed up for 14 days after SJ733 dosing. Phase 1a primary endpoints were safety, tolerability, and pharmacokinetics of SJ733, and identification of an SJ733 dose to test in the induced blood-stage malaria model. The phase 1b was a single-centre, open-label, volunteer infection study using the induced blood-stage malaria model in which fasted participants were intravenously infected with blood-stage P falciparum and subsequently treated with a single dose of SJ733. Phase 1b took place at Q-Pharm (Herston, QLD, Australia) and was initiated only after phase 1a showed that exposure exceeding the threshold minimum exposure could be safely achieved in humans. Participants were inoculated on day 0 with P falciparum-infected human erythrocytes (around 2800 parasites in the 150 mg dose cohort and around 2300 parasites in the 600 mg dose cohort), and parasitaemia was monitored before malaria inoculation, after inoculation, immediately before SJ733 dosing, and then post-dose. Participants were treated with SJ733 within 24 h of reaching 5000 parasites per mL or at a clinical score higher than 6. Phase 1b primary endpoints were calculation of a parasite reduction ratio (PRR48) and parasite clearance half-life, and safety and tolerability of SJ733 (incidence, severity, and drug-relatedness of adverse events). In both phases of the trial, SJ733 hydrochloride salt was formulated as a powder blend in capsules containing 75 mg or 300 mg for oral administration. Healthy men and women (of non-childbearing potential) aged 18-55 years were eligible for both studies. Both studies are registered with ClinicalTrials.gov (NCT02661373 for the phase 1a and NCT02867059 for the phase 1b). FINDINGS: In the phase 1a, 23 healthy participants were enrolled and received one to three non-consecutive doses of SJ733 between March 14 and Dec 7, 2016. SJ733 was safe and well tolerated at all doses and in fasted and fed conditions. 119 adverse events were recorded: 54 (45%) were unrelated, 63 (53%) unlikely to be related, and two (2%) possibly related to SJ733. In the phase 1b, 17 malaria-naive, healthy participants were enrolled. Seven participants in the 150 mg dose cohort were inoculated and dosed with SJ733. Eight participants in the 600 mg dose cohort were inoculated, but two participants could not be dosed with SJ733. Two additional participants were subsequently inoculated and dosed with SJ733. SJ733 exposure increased proportional to the dose through to the 600 mg dose, then was saturable at higher doses. Fasted participants receiving 600 mg exceeded the target area under the concentration curve extrapolated to infinity (AUC0-∞) of 13 000 μg × h/L (median AUC0-∞ 24 283 [IQR 16 135-31 311] μg × h/L, median terminal half-life 17·4 h [IQR 16·1-24·0], and median timepoint at which peak plasma concentration is reached 1·0 h [0·6-1·3]), and this dose was tested in the phase 1b. All 15 participants dosed with SJ733 had at least one adverse event. Of the 172 adverse events recorded, 128 (74%) were mild. The only adverse event attributed to SJ733 was mild bilateral foot paraesthesia that lasted 3·75 h and resolved spontaneously. The most common adverse events were related to malaria. Based on parasite clearance half-life, the derived log10PRR48 and corresponding parasite clearance half-lives were 2·2 (95% CI 2·0-2·5) and 6·47 h (95% CI 5·88-7·18) for 150 mg, and 4·1 (3·7-4·4) and 3·56 h (3·29-3·88) for 600 mg. INTERPRETATION: The favourable pharmacokinetic, tolerability, and safety profile of SJ733, and rapid antiparasitic effect support its development as a fast-acting component of combination antimalarial therapy. FUNDING: Global Health Innovative Technology Fund, Medicines for Malaria Venture, and the American Lebanese Syrian Associated Charities.
引用
- Gaur AH, McCarthy JS, Panetta JC, et al. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. Lancet Infect Dis. 2020. PMID: 32275867. doi:10.1016/S1473-3099(19)30611-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。